```
* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

NEWS  1           Web Page URLs for STN Seminar Schedule - N. America
NEWS  2  Apr 08   "Ask CAS" for self-help around the clock
NEWS  3  Apr 09   BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS  4  Apr 09   ZDB will be removed from STN
NEWS  5  Apr 19   US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
NEWS  6  Apr 22   Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS  7  Apr 22   BIOSIS Gene Names now available in TOXCENTER
NEWS  8  Apr 22   Federal Research in Progress (FEDRIP) now available
NEWS  9  Jun 03   New e-mail delivery for search results now available
NEWS 10  Jun 10   MEDLINE Reload
NEWS 11  Jun 10   PCTFULL has been reloaded
NEWS 12  Jul 02   FOREGE no longer contains STANDARDS file segment
NEWS 13  Jul 22   USAN to be reloaded July 28, 2002;
                  saved answer sets no longer valid
NEWS 14  Jul 29   Enhanced polymer searching in REGISTRY
NEWS 15  Jul 30   NETFIRST to be removed from STN
NEWS 16  Aug 08   CANCERLIT reload
NEWS 17  Aug 08   PHARMAMarketLetter(PHARMAML) - new on STN
NEWS 18  Aug 08   NTIS has been reloaded and enhanced
NEWS 19  Aug 19   Aquatic Toxicity Information Retrieval (AQUIRE)
                  now available on STN
NEWS 20  Aug 19   IFIPAT, IFICDB, and IFIUDB have been reloaded
NEWS 21  Aug 19   The MEDLINE file segment of TOXCENTER has been reloaded
NEWS 22  Aug 26   Sequence searching in REGISTRY enhanced
NEWS 23  Sep 03   JAPIO has been reloaded and enhanced
NEWS 24  Sep 16   Experimental properties added to the REGISTRY file
NEWS 25  Sep 16   Indexing added to some pre-1967 records in CA/CAPLUS
NEWS 26  Sep 16   CA Section Thesaurus available in CAPLUS and CA
NEWS 27  Oct 01   CASREACT Enriched with Reactions from 1907 to 1985

NEWS EXPRESS  February 1 CURRENT WINDOWS VERSION IS V6.0d,
              CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP),
              AND CURRENT DISCOVER FILE IS DATED 05 FEBRUARY 2002
NEWS HOURS    STN Operating Hours Plus Help Desk Availability
NEWS INTER    General Internet Information
NEWS LOGIN    Welcome Banner and News Items
NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *



FILE 'HOME' ENTERED AT 20:08:06 ON 03 OCT 2002

=> file reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.21       0.21

FILE 'REGISTRY' ENTERED AT 20:08:18 ON 03 OCT 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
```

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 2 OCT 2002 HIGHEST RN 458522-67-3
DICTIONARY FILE UPDATES: 2 OCT 2002 HIGHEST RN 458522-67-3

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=>
L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR

20 C M2

Page 1-A



Page 1-B

0 32 S 33



Page 1-D



Page 1-E



Page 1-F



Page 2-B



Page 2-C



Page 2-D



Page 2-E



```
Page 2-F
VAR G1=29/30
VAR G2=32/33
REP G19=(0-1) 20-19 20-23
REP G20=(0-1) 10-9 10-11
VPA 7-4/5/6 S
NODE ATTRIBUTES:
HCOUNT  IS M2     AT   9
HCOUNT  IS M2     AT  10
HCOUNT  IS M2     AT  19
HCOUNT  IS M2     AT  20
HCOUNT  IS M1     AT  23
HCOUNT  IS M1     AT  25
HCOUNT  IS M3     AT  29
HCOUNT  IS M2     AT  30
HCOUNT  IS E3     AT  31
NSPEC   IS R      AT   1
NSPEC   IS R      AT   2
NSPEC   IS R      AT   3
NSPEC   IS R      AT   4
NSPEC   IS R      AT   5
NSPEC   IS R      AT   6
NSPEC   IS C      AT   7
NSPEC   IS C      AT   8
NSPEC   IS C      AT   9
NSPEC   IS C      AT  10
NSPEC   IS C      AT  11
NSPEC   IS R      AT  12
NSPEC   IS R      AT  13
NSPEC   IS R      AT  14
NSPEC   IS R      AT  15
NSPEC   IS R      AT  16
NSPEC   IS R      AT  17
NSPEC   IS C      AT  18
NSPEC   IS C      AT  19
NSPEC   IS C      AT  20
NSPEC   IS R      AT  21
NSPEC   IS R      AT  22
NSPEC   IS R      AT  23
NSPEC   IS R      AT  24
NSPEC   IS R      AT  25
NSPEC   IS C      AT  26
NSPEC   IS C      AT  27
NSPEC   IS C      AT  28
DEFAULT MLEVEL IS ATOM
MLEVEL  IS CLASS  AT   7  9 10 19 20 29 30 31 32 33
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
```

```
RSPEC I
NUMBER OF NODES IS  33

STEREO ATTRIBUTES: NONE


=> s l1
SAMPLE SEARCH INITIATED 20:14:05 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -     10 TO ITERATE

100.0% PROCESSED      10 ITERATIONS                                 2 ANSWERS
SEARCH TIME: 00.00.02

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:           11 TO      389
PROJECTED ANSWERS:               2 TO      124

L2             2 SEA SSS SAM L1

=> s l1 full
THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 139.90 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y
FULL SEARCH INITIATED 20:14:18 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    310 TO ITERATE

100.0% PROCESSED     310 ITERATIONS                                48 ANSWERS
SEARCH TIME: 00.00.06

L3            48 SEA SSS FUL L1

=> file hcaplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                     143.70     143.91

FILE 'HCAPLUS' ENTERED AT 20:14:30 ON 03 OCT 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
the American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 3 Oct 2002  VOL 137 ISS 14
FILE LAST UPDATED: 2 Oct 2002  (20021002/ED)

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

CAS roles have been modified effective December 16, 2001. Please
check your SDI profiles to see if they need to be revised. For
information on CAS roles, enter HELP ROLES at an arrow prompt or use
the CAS Roles thesaurus (/RL field) in this file.

=> s l3
L4          490 L3
```

```
=> s l3/thu
          490 L3
       466819 THU/RL
L5        324 L3/THU
                (L3 (L) THU/RL)

=> s l5 and method
      2340863 METHOD
       982149 METHODS
      3048039 METHOD
                (METHOD OR METHODS)
L6         92 L5 AND METHOD

=> s l6 and diab?
        94540 DIAB?
L7         56 L6 AND DIAB?

=> s l7 and mellit?
        53014 MELLIT?
L8         44 L7 AND MELLIT?

=> s l8 and pd < may 20 1999
     19621278 PD < MAY 20 1999
                (PD<19990520)
L9         17 L8 AND PD < MAY 20 1999

=> d l9, ibib abs fhitstr, 1-17

L9   ANSWER 1 OF 17  HCAPLUS  COPYRIGHT 2002 ACS
```

Full Text | Citing References

ACCESSION NUMBER: 2000:362595 HCAPLUS
DOCUMENT NUMBER: 133:13403
TITLE: Adipocyte containing ob gene promoter for screening modulators useful in treatment of anorexia, obesity, and other diseases
INVENTOR(S): Briggs, Michael R.; Auwerx, Johan; De Vos, Piet; Staels, Bart; Croston, Glenn E.; Miller, Stephen G.
PATENT ASSIGNEE(S): Ligand Pharmaceuticals Inc., USA
SOURCE: U.S., 64 pp., Cont.-in-part of U.S. Ser. No. 558,588, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6068976	A	20000530	US 1996-618100	19960319
CA 2215387	**AA**	**19960926**	**CA 1996-2215387**	**19960319**

PRIORITY APPLN. INFO.:

US 1995-408584	B2	19950320
US 1995-418096	B2	19950405
US 1995-510584	B2	19950802
US 1995-558588	B2	19951030
US 1995-7390P	P	19951121
US 1995-7721P	P	19951130
US 1995-8601P	P	19951214

AB This invention relates to the isolation and cloning of the promoter and other control regions of a human ob gene. It provides a **method** for identifying and screening for agents useful for the treatment of diseases and pathol. conditions affected by the level of expression of an ob gene. These agents interact directly or indirectly with the promoter or other

control regions of the ob gene. A PPARγ agonist, BRL49653, has been identified to be useful in treating anorexia, cachexia, and other diseases characterized by insufficient food intake or body wt. loss. Modulators of ob gene expression may be used to treat other diseases such as obesity, **diabetes**, hypertension, cardiovascular diseases and infertility.

IT **122320-73-4**, BRL49653
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(PPARγ agonist; adipocyte contg. ob gene promoter for screening modulators useful in treatment of anorexia, obesity, and other diseases)

RN 122320-73-4 HCAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 2 OF 17 HCAPLUS COPYRIGHT 2002 ACS

Full Text | Citing References

ACCESSION NUMBER: 1999:316557 HCAPLUS
DOCUMENT NUMBER: 130:332912
TITLE: Activators of the nuclear orphan receptor peroxisome proliferator-activated receptor gamma for treatment of **diabetes** and cardiovascular disorders
INVENTOR(S): Kliewer, Steven Anthony; Lehmann, Jurgen M.; Willson, Timothy M.
PATENT ASSIGNEE(S): Glaxo Wellcome Inc., USA
SOURCE: U.S., 9 pp., Cont. of U.S. Ser. No. 804,310, abandoned.

CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5902726	**A**	**19990511**	**US 1998-28988**	**19980225**
US 5994554	A	19991130	US 1998-207936	19981209

PRIORITY APPLN. INFO.:

US 1994-363482	19941223
US 1995-386394	19950210
US 1997-804310	19970221
US 1998-28988	19980225

OTHER SOURCE(S): MARPAT 130:332912

AB The present invention provides activator compds., including agonists, to the peroxisome proliferator-activated receptor gamma. Particular PPARγ activators are set forth, as are a pharmaceutical compn. for treating **diabetes**, non-insulin-dependent **diabetes mellitus**, cardiovascular disorders, and **methods** for such treatment. Also claimed is a **method** of identifying activator compds.

IT **173792-21-7**
RL: ARG (Analytical reagent use); **THU (Therapeutic use)**; BSU (Biological study, unclassified); **THU (Therapeutic use)**; ANST (Analytical study); BIOL (Biological study); PROC (Process); USES (Uses)
(for identifying PPAR γ-interacting compds. useful as drugs; activators of peroxisome proliferator-activated receptor gamma for treatment of **diabetes** and cardiovascular disorders)

RN 173792-21-7 HCAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-, labeled with tritium (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 3 OF 17 HCAPLUS COPYRIGHT 2002 ACS

Full Text | Citing References

ACCESSION NUMBER: 1999:167677 HCAPLUS
DOCUMENT NUMBER: 131:124868
TITLE: Systemic exposure to rosiglitazone is unaltered by food
AUTHOR(S): Freed, M. I.; Allen, A.; Jorkasky, D. K.; DiCicco, R. A.
CORPORATE SOURCE: SmithKline Beecham Clinical Pharmacology Unit, Presbyterian Medical Center of the University of Pennsylvania Health System, 51 North 39th Street, Philadelphia, PA, 19104, USA
SOURCE: European Journal of Clinical Pharmacology (**1999**), 55(1), 53-56
CODEN: EJCPAS; ISSN: 0031-6970
PUBLISHER: Springer-Verlag
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Objective: To evaluate the effect of food on the bioavailability and pharmacokinetics of the insulin sensitizer rosiglitazone. **Methods**: In a randomized, open-label, period-balanced, single-dose, crossover study, rosiglitazone 2 mg was administered to 12 healthy male volunteers either in the fasting state or following a std. high-fat breakfast. The primary end points of the study were AUC0-inf and Cmax. Results: Single oral doses of rosiglitazone were safe and well tolerated. Overall exposure to rosiglitazone was unaffected by food. The geometric mean ratio of AUC(0-inf) in the fed:fasted regimens was 0.94 (95% CI: 0.82, 1.06); t1/2was unaffected. Absorption of rosiglitazone in the fed state was more gradual and sustained than in the fasted state. Cmax was reduced by approx. 20% (point est. 0.80; 95% CI 0.65 to 0.97) and tmax was modestly delayed in the fed state. Conclusion: These data support dosing guidelines that will permit the administration of rosiglitazone without regard to meals for treatment of type 2 **diabetes mellitus**.

IT **122320-73-4**, Rosiglitazone
RL: BPR (Biological process); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); PROC (Process); USES (Uses)
(bioavailability of antidiabetic rosiglitazone is unaltered by food intake in humans)

RN 122320-73-4 HCAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 4 OF 17 HCAPLUS COPYRIGHT 2002 ACS

Full Text | Citing References

ACCESSION NUMBER: 1999:81575 HCAPLUS
DOCUMENT NUMBER: 130:134189
TITLE: Treatment of **diabetes** with a thiazolidinedione, an insulin secretagogue, and an α-glucosidase inhibitor
INVENTOR(S): Buckingham, Robin Edwin; Smith, Stephen Alistair
PATENT ASSIGNEE(S): Smithkline Beecham PLC, UK
SOURCE: PCT Int. Appl., 20 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9903478	**A1**	**19990128**	**WO 1998-GB2112**	**19980716**
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9884490	**A1**	**19990210**	**AU 1998-84490**	**19980716**
EP 1001784	A1	20000524	EP 1998-935129	19980716

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO

BR 9810292	A	20000919	BR 1998-10292		19980716
JP 2001510160	T2	20010731	JP 2000-502777		19980716
ZA 9806364	A	20000117	ZA 1998-6364		19980717
NO 2000000230	A	20000117	NO 2000-230		20000117
US 2002052324	A1	20020502	US 2001-989572		20011120
PRIORITY APPLN. INFO.:			GB 1997-15298	A	19970718
			WO 1998-GB2112	W	19980716
			US 1999-445908	A1	19991215

AB A **method** and compn. are disclosed for the treatment of **diabetes mellitus** and conditions assocd. with **diabetes mellitus** in a mammal. The **method** comprises administering an effective nontoxic and pharmaceutically acceptable amt. of an insulin sensitizer, an insulin secretagogue and an α-glucosidase inhibitor antihyperglycemic agent to a mammal in need thereof.

IT **122320-73-4**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)

(thiazolidinedione, insulin secretagogue, and α-glucosidase inhibitor for **diabetes** treatment)

RN 122320-73-4 HCAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 5 OF 17 HCAPLUS COPYRIGHT 2002 ACS

Full Text | Citing References

ACCESSION NUMBER: 1999:81574 HCAPLUS
DOCUMENT NUMBER: 130:134188
TITLE: Treatment of **diabetes** with a thiazolidinedione, an insulin secretagogue, and a biguanide
INVENTOR(S): Buckingham, Robin Edwin; Smith, Stephen Alistair
PATENT ASSIGNEE(S): Smithkline Beecham PLC, UK
SOURCE: PCT Int. Appl., 19 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9903477	**A1**	**19990128**	**WO 1998-GB2110**	**19980716**
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9884488	**A1**	**19990210**	**AU 1998-84488**	**19980716**
EP 1001783	A1	20000524	EP 1998-935127	19980716
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO				
BR 9810445	A	20000905	BR 1998-10445	19980716
JP 2001510159	T2	20010731	JP 2000-502776	19980716
ZA 9806363	A	20000117	ZA 1998-6363	19980717
NO 2000000228	A	20000117	NO 2000-228	20000117
US 2002016287	A1	20020207	US 2001-939470	20010824

PRIORITY APPLN. INFO.:

GB 1997-15295	A	19970718
WO 1998-GB2110	W	19980716
US 1999-446039	A1	19991215

AB A **method** and compn. are disclosed for the treatment of **diabetes mellitus** and conditions assocd. with **diabetes mellitus** in a mammal. The **method** comprises administering an effective nontoxic and pharmaceutically acceptable amt. of an insulin sensitizer, an insulin secretagogue and a biguanide antihyperglycemic agent to a mammal in need thereof.

IT **122320-73-4**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(thiazolidinedione, insulin secretagogue, and biguanide for **diabetes** treatment)

RN 122320-73-4 HCAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 6 OF 17 HCAPLUS COPYRIGHT 2002 ACS

Full Text | Citing References

ACCESSION NUMBER: 1999:81573 HCAPLUS
DOCUMENT NUMBER: 130:134187
TITLE: Treatment of **diabetes** with insulin sensitizer thiazolidinedione and insulin secretagogue sulfonylurea
INVENTOR(S): Buckingham, Robin Edwin; Smith, Stephen Alistair
PATENT ASSIGNEE(S): Smithkline Beecham PLC, UK
SOURCE: PCT Int. Appl., 19 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9903476	**A1**	**19990128**	**WO 1998-GB2109**	**19980716**
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9884487	**A1**	**19990210**	**AU 1998-84487**	**19980716**
AU 743269	B2	20020124		

EP 998291	A1	20000510	EP 1998-935126	19980716
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO				
BR 9810904	A	20000926	BR 1998-10904	19980716
JP 2001510158	T2	20010731	JP 2000-502775	19980716
ZA 9806365	A	20000117	ZA 1998-6365	19980717
NO 2000000229	A	20000117	NO 2000-229	20000117
US 2002045649	A1	20020418	US 2001-975883	20011012

PRIORITY APPLN. INFO.:

GB 1997-15306	A	19970718
WO 1998-GB2109	W	19980716
US 1999-445907	A1	19991215

AB A **method** for the treatment of **diabetes mellitus** and conditions assocd. with **diabetes mellitus** in a mammal, which **method** comprises administering an effective non-toxic and pharmaceutically acceptable amt. of an insulin sensitizer and a sub-maximal amt. of an insulin secretagogue, to a mammal in need thereof; and a pharmaceutical compn. for use in such **method** are disclosed. The insulin secretagogue is esp. sulfonylurea. The insulin sensitizer is esp. 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione (I). Tablet formulations contg. I maleate are given.

IT **122320-73-4**

RL: **THU (Therapeutic use)**; BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); PROC (Process); USES (Uses)

(as insulin sensitizer; treatment of **diabetes** with insulin sensitizer thiazolidinedione and insulin secretagogue sulfonylurea)

RN 122320-73-4 HCAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 7 OF 17 HCAPLUS COPYRIGHT 2002 ACS

Full Text | Citing References

ACCESSION NUMBER: 1999:9712 HCAPLUS
DOCUMENT NUMBER: 130:61091
TITLE: Treatment of **diabetes** with thiazolidinedione and sulfonylurea
INVENTOR(S): Smith, Stephen Alistair
PATENT ASSIGNEE(S): Smithkline Beecham Plc, UK
SOURCE: PCT Int. Appl., 20 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9857649	**A1**	**19981223**	**WO 1998-EP3688**	**19980615**
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9885392	**A1**	**19990104**	**AU 1998-85392**	**19980615**
EP 999845	A1	20000517	EP 1998-936363	19980615
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO				
BR 9810142	A	20000808	BR 1998-10142	19980615
JP 2001523270	T2	20011120	JP 1999-503754	19980615
ZA 9805236	A	20000217	ZA 1998-5236	19980617
NO 9906264	A	20000217	NO 1999-6264	19991217
US 2001049380	A1	20011206	US 2001-848511	20010502

PRIORITY APPLN. INFO.:

GB 1997-12854	A	19970618
GB 1998-6710	A	19980327
WO 1998-EP3688	W	19980615
US 1999-445859	B1	19991215

AB A **method** for the treatment of **diabetes mellitus** and conditions assocd. with **diabetes mellitus** in a mammal, which **method** comprises administering an effective nontoxic and pharmaceutically acceptable amt. of an insulin sensitizer and an insulin secretagogue, to a mammal in need thereof.

IT **155141-29-0**, Rosiglitazone maleate
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(treatment of **diabetes** with thiazolidinedione and sulfonylurea)

RN 155141-29-0 HCAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 122320-73-4
CMF C18 H19 N3 O3 S

PAGE 1-A



PAGE 2-A



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 8 OF 17 HCAPLUS COPYRIGHT 2002 ACS

Full Text | Citing References

ACCESSION NUMBER: 1999:9699 HCAPLUS
DOCUMENT NUMBER: 130:61090
TITLE: Treatment of **diabetes** with rosiglitazone and insulin
INVENTOR(S): Smith, Stephen Alistair
PATENT ASSIGNEE(S): Smithkline Beecham P.L.C., UK
SOURCE: PCT Int. Appl., 17 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 9857636	**A1**	**19981223**	**WO 1998-EP3692**	**19980615**
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9882163	**A1**	**19990104**	**AU 1998-82163**	**19980615**
EP 999837	A1	20000517	EP 1998-932169	19980615
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO				
BR 9810444	A	20000905	BR 1998-10444	19980615
JP 2002504138	T2	20020205	JP 1999-503757	19980615
ZA 9805237	A	20000217	ZA 1998-5237	19980617
NO 9906265	A	19991217	NO 1999-6265	19991217
US 2002028768	A1	20020307	US 2001-928326	20010813

PRIORITY APPLN. INFO.:

GB 1997-12866	A	19970618
WO 1998-EP3692	W	19980615
US 1999-445858	B1	19991215

AB A **method** for the treatment of **diabetes mellitus** and conditions assocd. with **diabetes mellitus** in a mammal, which **method** comprises administering an effective nontoxic and pharmaceutically acceptable amt. of insulin sensitizer rosiglitazone and insulin to a mammal in need thereof.

IT **155141-29-0**, Rosiglitazone maleate
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(treatment of **diabetes mellitus** with rosiglitazone and insulin)

RN 155141-29-0 HCAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 122320-73-4
CMF C18 H19 N3 O3 S

PAGE 1-A



PAGE 2-A



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 9 OF 17 HCAPLUS COPYRIGHT 2002 ACS

Full Text | Citing References

ACCESSION NUMBER: 1999:9698 HCAPLUS
DOCUMENT NUMBER: 130:76189
TITLE: Treatment of **diabetes** with thiazolidinedione and alpha-glucosidase inhibitor
INVENTOR(S): Smith, Stephen Alistair
PATENT ASSIGNEE(S): Smithkline Beecham Plc, UK
SOURCE: PCT Int. Appl., 19 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9857635	**A1**	**19981223**	**WO 1998-EP3691**	**19980615**
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9887999	**A1**	**19990104**	**AU 1998-87999**	**19980615**
EP 975343	A1	20000202	EP 1998-939513	19980615
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO				
BR 9810186	A	20000808	BR 1998-10186	19980615
JP 2001523271	T2	20011120	JP 1999-503756	19980615
ZA 9805235	A	20000217	ZA 1998-5235	19980617
NO 9906270	A	19991217	NO 1999-6270	19991217
US 2001034356	A1	20011025	US 2001-863136	20010523
US 2002123514	A1	20020905	US 2002-91008	20020305

PRIORITY APPLN. INFO.:

GB 1997-12865	A	19970618
GB 1998-6708	A	19980327
WO 1998-EP3691	W	19980615

US 1999-445951 B1 19991215
US 2001-863136 B1 20010523

GI



I

AB A **method** for the treatment of **diabetes mellitus** and conditions assocd. with **diabetes mellitus** in a mammal, which **method** comprises administering an effective non-toxic and pharmaceutically acceptable amt. of an insulin sensitizer (I) and an α-glucosidase inhibitor antihyperglycemic agent. The effects of α-glucosidase inhibitor acarbose on the pharmacokinetics of I in healthy humans are described along with pharmaceutical formulations (concns. and tablets) contg. I.

IT **155141-29-0**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(treatment of **diabetes mellitus** and conditions assocd. with **diabetes** with thiazolidinedione deriv. and α-glucosidase inhibitors)

RN 155141-29-0 HCAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 122320-73-4
CMF C18 H19 N3 O3 S

PAGE 1-A



PAGE 2-A



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 10 OF 17 HCAPLUS COPYRIGHT 2002 ACS

Full Text | Citing References

ACCESSION NUMBER: 1999:9697 HCAPLUS
DOCUMENT NUMBER: 130:61089
TITLE: Treatment of **diabetes** with thiazolidinedione and metformin
INVENTOR(S): Smith, Stephen Alistair
PATENT ASSIGNEE(S): Smithkline Beecham Plc, UK
SOURCE: PCT Int. Appl., 20 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 9857634		**A1**	**19981223**	**WO 1998-EP3690**	**19980615**
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9885393		**A1**	**19990104**	**AU 1998-85393**	**19980615**
EP 996444		A1	20000503	EP 1998-936364	19980615
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO				
BR 9810172		A	20000808	BR 1998-10172	19980615
JP 2002504137		T2	20020205	JP 1999-503755	19980615
ZA 9805238		A	20000217	ZA 1998-5238	19980617
NO 9906266		A	19991217	NO 1999-6266	19991217
US 2002004515		A1	20020110	US 2001-925394	20010809
US 2002137772		A1	20020926	US 2002-99161	20020313

PRIORITY APPLN. INFO.:	GB 1997-12857	A	19970618
	GB 1998-6706	A	19980327
	WO 1998-EP3690	W	19980615
	US 1999-446030	B1	19991215
	US 2001-925394	B1	20010809

AB A **method** for the treatment and/or prophylaxis of **diabetes mellitus**, conditions assocd. with **diabetes mellitus**, and certain complications thereof, in a mammal which **method** comprises administering an effective nontoxic and pharmaceutically acceptable amt. of an insulin sensitizer rosiglitazone (I) and a biguanide antihyperglycemic agent such as metformin. Pharmacokinetics of I and metformin administered alone or in combination are described. Formulations for prepg. tablets contg. I is presented.

IT **155141-29-0**, Rosiglitazone maleate
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(treatment of **diabetes** with thiazolidinedione insulin sensitizer and metformin)

RN 155141-29-0 HCAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 122320-73-4
CMF C18 H19 N3 O3 S

PAGE 1-A



PAGE 2-A



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 11 OF 17 HCAPLUS COPYRIGHT 2002 ACS

Full Text | Citing References

ACCESSION NUMBER: 1998:764284 HCAPLUS
DOCUMENT NUMBER: 130:10664
TITLE: Use of 5-(4-(2-(N-methyl-N-(2-pyridyl)amino)ethoxy)benzyl)-2,4-thiazolidinedione in the treatment of polycystic ovary syndrome and gestational **diabetes**
INVENTOR(S): Antonucci, Tammy; Lockwood, Dean; Norris, Rebecca
PATENT ASSIGNEE(S): Warner-Lambert Company, USA
SOURCE: PCT Int. Appl., 55 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 7
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9851305	**A1**	**19981119**	**WO 1998-US10113**	**19980514**
W: AL, AU, BA, BB, BG, BR, CA, CN, CZ, EE, GE, GW, HU, ID, IL, IS, JP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
ZA 9804084	**A**	**19981120**	**ZA 1998-4084**	**19980514**
AU 9874949	**A1**	**19981208**	**AU 1998-74949**	**19980514**
AU 731690	B2	20010405		
EP 981346	A1	20000301	EP 1998-922391	19980514
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 9809120	A	20000801	BR 1998-9120	19980514
JP 2001525827	T2	20011211	JP 1998-549654	19980514
AU 9952576	A1	19991202	AU 1999-52576	19991001
AU 749416	B2	20020627		
NO 9905549	A	19991112	NO 1999-5549	19991112

PRIORITY APPLN. INFO.:		
US 1997-856987	A	19970515
AU 1997-17709	A3	19970403
WO 1998-US10113	W	19980514

AB Novel **methods** of using thiazolidinone derivs. and related antihyperglycemic agents to treat populations at risk for developing noninsulin-dependent **diabetes mellitus** (NIDDM) and complications arising therefrom are disclosed. In one embodiment, the compds. of the invention are used to treat polycystic ovary syndrome to prevent or delay the onset of noninsulin-dependent **diabetes mellitus**. In another embodiment, the compds. of the invention are used to treat gestational **diabetes** to prevent or delay the onset of noninsulin-dependent **diabetes mellitus**.

IT **122320-73-4**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)

(ste ns treatment of polycystic ovary syndrome and gestational **diabetes** and prevention of NIDDM development by (methyl)pyridyl)

RN 122320-73-4 HCAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 12 OF 17 HCAPLUS COPYRIGHT 2002 ACS

Full Text | Citing References

ACCESSION NUMBER: 1998:672463 HCAPLUS
DOCUMENT NUMBER: 129:270626
TITLE: **Methods** and compositions for treating and/or preventing non-insulin dependent **diabetes mellitus** (NIDDM) using specific retinoid compounds
INVENTOR(S): Pfahl, Magnus; Lernhardt, Waldemar; Fanjol, Andrea
PATENT ASSIGNEE(S): Centre International de Recherches Dermatologiques Galderma, Fr.
SOURCE: PCT Int. Appl., 21 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9842340	**A1**	**19981001**	**WO 1998-US5591**	**19980324**
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9865763	**A1**	**19981020**	**AU 1998-65763**	**19980324**

EP 1019049	A1	20000719	EP 1998-911919		19980324
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI					
BR 9808054	A	20001107	BR 1998-8054		19980324
JP 2001521551	T2	20011106	JP 1998-545851		19980324
NO 9904612	A	19991124	NO 1999-4612		19990902
PRIORITY APPLN. INFO.:			US 1997-35604P	P	19970324
			WO 1998-US5591	W	19980324

AB **Methods** are provided for treating and/or preventing non-insulin dependent **diabetes mellitus** (NIDDM) in subjects having or at substantial risk of developing NIDDM, using specific retinoid compds. that are structurally related to 9-cis retinoid acid which induce the differentiation of preadipocytes into adipocytes. These compds. may be administered alone or in combination with other anti-**diabetogenic** agents such as thiazolidinediones.

IT **122320-73-4**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(retinoid compds. with other agents for treating and/or preventing non-insulin dependent **diabetes mellitus**)

RN 122320-73-4 HCAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



L9 ANSWER 13 OF 17 HCAPLUS COPYRIGHT 2002 ACS

Full Text | Citing References

ACCESSION NUMBER: 1998:41808 HCAPLUS
DOCUMENT NUMBER: 128:123811
TITLE: Use of thiazolidinedione derivatives and related

antihyperglycemic agents in the treatment of insulin-resistant subjects with normal glucose tolerance in order to prevent or delay the onset of noninsulin-dependent **diabetes mellitus**

INVENTOR(S): Olefsky, Jerrold M.
PATENT ASSIGNEE(S): Sankyo Company, Limited, Japan
SOURCE: U.S., 16 pp.
CODEN: USXXAM

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5708012	A	19980113	US 1995-431266	19950428

OTHER SOURCE(S): MARPAT 128:123811

AB **Methods** are disclosed for using thiazolidinone derivs. and related antihyperglycemic agents to treat populations exhibiting insulin-resistant non-impaired glucose tolerance in order to prevent or delay the onset of noninsulin-dependent **diabetes mellitus** and complications arising therefrom. In an outpatient trial with nondiabetic, obese patients, some of whom had impaired glucose tolerance, (+)-5-[[4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]phenyl]methyl]-2,4-thiazolidinedione (troglitazone) normalized glucose tolerance and markedly improved insulin resistance and hyperinsulinemia.

IT **122320-73-4**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(thiazolidinedione derivs. and related antihyperglycemic agents in treatment of insulin-resistant subjects with normal glucose tolerance to prevent or delay onset of noninsulin-dependent **diabetes mellitus**)

RN 122320-73-4 HCAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A





L9 ANSWER 14 OF 17 HCAPLUS COPYRIGHT 2002 ACS

Full Text | Citing References

ACCESSION NUMBER: 1997:329275 HCAPLUS
DOCUMENT NUMBER: 126:308792
TITLE: Treating NIDDM with RXR agonists
INVENTOR(S): Heyman, Richard A.; Cesario, Rosemary; Mukherjee, Ranjan
PATENT ASSIGNEE(S): Ligand Pharmaceuticals Incorporated, USA
SOURCE: PCT Int. Appl., 56 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9710819	**A1**	**19970327**	**WO 1996-US14904**	**19960917**
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML				
CA 2232288	**AA**	**19970327**	**CA 1996-2232288**	**19960917**
AU 9670742	**A1**	**19970409**	**AU 1996-70742**	**19960917**
AU 725998	B2	20001026		
EP 859608	**A1**	**19980826**	**EP 1996-931613**	**19960917**
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
BR 9610624	**A**	**19990316**	**BR 1996-10624**	**19960917**
JP 11511472	T2	19991005	JP 1996-512842	19960917
US 6028052	A	20000222	US 1996-710309	19960917
US 5972881	A	19991026	US 1997-979725	19971126
NO 9801192	**A**	**19980518**	**NO 1998-1192**	**19980317**
US 6228862	B1	20010508	US 1999-309370	19990511
US 6316404	B1	20011113	US 2000-745681	20001222

PRIORITY APPLN. INFO.:

US 1995-3869P	P	19950918
US 1995-4897P	P	19951006
US 1996-9884P	P	19960110
US 1996-18318P	P	19960524
US 1996-21839P	P	19960710
US 1996-710309	B3	19960917
WO 1996-US14904	W	19960917
US 1997-979725	A1	19971126
US 1999-309370	A3	19990511

AB This invention relates to **methods** and compns. for the treatment of non-insulin-dependent **diabetes mellitus** using an RXR agonist alone or in combination with a PPARγ agonist such as thiazolidine dione compd. Example RXR agonists are LGD 1069, ALRT 1957 and LG 100268.

IT **122320-73-4**, BRL 49653
RL: **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(noninsulin dependent **diabetes** treatment with RXR agonists)

RN 122320-73-4 HCAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]met

hyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



L9 ANSWER 15 OF 17 HCAPLUS COPYRIGHT 2002 ACS

Full Text | Citing References

ACCESSION NUMBER: 1997:231131 HCAPLUS
DOCUMENT NUMBER: 126:207528
TITLE: A thiazolidione derivative for reducing the amount of exogenous insulin administered to a patient having noninsulin-dependent **diabetes mellitus**
INVENTOR(S): Whitcomb, Randall W.
PATENT ASSIGNEE(S): Warner-Lambert Company, USA; Whitcomb, Randall W.
SOURCE: PCT Int. Appl., 43 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9705875	**A2**	**19970220**	**WO 1996-US12430**	**19960729**
WO 9705875	A3	19970327		
W: AU, BG, CA, CN, CZ, EE, GE, HU, IL, JP, KR, LT, LV, MX, NO, NZ, PL, RO, SG, SI, SK, UA, US, UZ, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2221241	**AA**	**19970220**	**CA 1996-2221241**	**19960729**
AU 9666411	**A1**	**19970305**	**AU 1996-66411**	**19960729**
AU 724989	B2	20001005		
EP 851757	**A2**	**19980708**	**EP 1996-926171**	**19960729**
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

IE, SI, LT, LV, FI

CN 1192683	**A**	**19980909**	**CN 1996-196191**		**19960729**
JP 11510508	T2	19990914	JP 1996-508479		19960729
NO 9800556	**A**	**19980209**	**NO 1998-556**		**19980209**
PRIORITY APPLN. INFO.:			US 1995-2098P	P	19950810
			WO 1996-US12430	W	19960729

OTHER SOURCE(S): MARPAT 126:207528

AB This invention provides a **method** of reducing the amt. of exogenous insulin administered to a patient having noninsulin-dependent **diabetes mellitus** by administering to a patient a therapeutically effective amt. of a thiazolidione deriv. and/or a related compd. Seventeen patients with noninsulin-dependent **diabetes mellitus** that were still on insulin were treated with thiazolidinedione deriv. (400 mg/day) for 8 wk. Ten patients have had a mean decrease of 45% (39 units) in their daily dose of insulin and appear to be continuing to reduce their insulin requirements. At the same time, their glycemic control was improving with a mean decrease of 15% (36 mg/dL) in blood glucose. A total of 7 patients have had their insulin discontinued after 8 wk.

IT **122320-73-4**, BRL 49653
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(thiazolidione deriv. and/or related compds. for reducing amt. of exogenous insulin in humans with noninsulin-dependent **diabetes mellitus**)

RN 122320-73-4 HCAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



L9 ANSWER 16 OF 17 HCAPLUS COPYRIGHT 2002 ACS

Full Text | Citing References

ACCESSION NUMBER: 1996:713048 HCAPLUS
DOCUMENT NUMBER: 125:319877
TITLE: Adipocyte containing ob gene promoter for screening modulators useful in treatment of anorexia, obesity, and other diseases
INVENTOR(S): Briggs, Michael R.; Auwerx, Johan; De Vos, Piet; Staels, Bart; Croston, Glenn E.; Miller, Stephen G.
PATENT ASSIGNEE(S): Ligand Pharmaceuticals Incorporated, USA; Institut Pasteur De Lille
SOURCE: PCT Int. Appl., 166 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9629405	**A2**	**19960926**	**WO 1996-US3808**	**19960319**
WO 9629405	A3	19961128		
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML				
CA 2215387	**AA**	**19960926**	**CA 1996-2215387**	**19960319**
AU 9655248	**A1**	**19961008**	**AU 1996-55248**	**19960319**
EP 815230	**A2**	**19980107**	**EP 1996-912428**	**19960319**
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				

PRIORITY APPLN. INFO.:

US 1995-408584	A	19950320
US 1995-418096	A	19950405
US 1995-510584	A	19950802
US 1995-558588	A	19951030
US 1995-7390P	P	19951121
US 1995-7721P	P	19951130
US 1995-8601P	P	19951214
WO 1996-US3808	W	19960319

AB This invention relates to the isolation and cloning of the promoter and other control regions of a human ob gene. It provides a **method** for identifying and screening for agents useful for the treatment of diseases and pathol. conditions affected by the level of expression of an ob gene. These agents interact directly or indirectly with the promoter or other control regions of the ob gene. A PPARγ agonist, BRL49653, has been identified to be useful in treating anorexia, cachexia, and other diseases characterized by insufficient food intake or body wt. loss. Modulators of ob gene expression may be used to treat other diseases such as obesity, **diabetes**, hypertension, cardiovascular diseases and infertility.

IT **122320-73-4**, BRL49653
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(PPARγ agonist; adipocyte contg. ob gene promoter for screening modulators useful in treatment of anorexia, obesity, and other diseases)

RN 122320-73-4 HCAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



L9 ANSWER 17 OF 17 HCAPLUS COPYRIGHT 2002 ACS

Full Text | Citing References

ACCESSION NUMBER: 1996:71475 HCAPLUS
DOCUMENT NUMBER: 124:106679
TITLE: Thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of impaired glucose tolerance to prevent or delay the onset of noninsulin-dependent **diabetes mellitus**
INVENTOR(S): Olefsky, Jerrold; Antonucci, Tammy; Lockwood, Dean; Norris, Rebecca
PATENT ASSIGNEE(S): Sankyo Co., Ltd., Japan
SOURCE: U.S., 15 pp. Cont.-in-part of U.S. Ser. No. 122,251, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 7
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5478852	**A**	**19951226**	**US 1994-293899**	**19940823**
US 5478852	C1	20010313		
WO 9507697	**A2**	**19950323**	**WO 1994-US10187**	**19940909**
WO 9507697	A3	19950511		
W: AU, CA, CN, CZ, FI, HU, JP, KR, NO, NZ, RU, SK				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
WO 9507694	**A1**	**19950323**	**WO 1994-US10389**	**19940914**
W: AU, CA, CN, CZ, FI, HU, JP, KR, MW, NO, NZ, RU				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9478351	**A1**	**19950403**	**AU 1994-78351**	**19940914**

AU 679572	B2	19970703			
EP 719140	**A1**	**19960703**	**EP 1994-929204**	**19940914**	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE					
CN 1134669	**A**	**19961030**	**CN 1994-194058**	**19940914**	
JP 09502727	**T2**	**19970318**	**JP 1995-509333**	**19940914**	
JP 3081245	B2	20000828			
HU 75874	**A2**	**19970528**	**HU 1996-653**	**19940914**	
CZ 283207	**B6**	**19980114**	**CZ 1996-2822**	**19940914**	
CZ 283208	**B6**	**19980114**	**CZ 1996-2823**	**19940914**	
CZ 283339	**B6**	**19980318**	**CZ 1996-793**	**19940914**	
JP 2000239167	A2	20000905	JP 2000-71978	19940914	
JP 2000273043	A2	20001003	JP 2000-71977	19940914	
NO 9601041	**A**	**19960514**	**NO 1996-1041**	**19960314**	
FI 9601213	**A**	**19960514**	**FI 1996-1213**	**19960315**	
AU 9717709	**A1**	**19970529**	**AU 1997-17709**	**19970403**	
AU 706947	B2	19990701			
AU 9717710	**A1**	**19970529**	**AU 1997-17710**	**19970403**	
AU 9952576	A1	19991202	AU 1999-52576	19991001	
AU 749416	B2	20020627			
NO 2000002963	A	20000609	NO 2000-2963	20000609	
NO 2000002964	A	20000609	NO 2000-2964	20000609	

PRIORITY APPLN. INFO.:

US 1993-122251	B2	19930915
US 1994-292585	A	19940823
US 1994-293899		19940823
JP 1994-509333	A3	19940914
JP 1995-509333	A3	19940914
WO 1994-US10389	W	19940914
AU 1997-17709	A3	19970403

OTHER SOURCE(S): MARPAT 124:106679

AB Novel **methods** of using thiazolidinone derivs. and related antihyperglycemic agents to treat populations experiencing impaired glucose tolerance in order to prevent or delay the onset of noninsulin-dependent **diabetes mellitus** and complications arising therefrom, are disclosed. Effects of (+)-5-[[4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]phenyl]methyl]-2,4-thiazolidinedione (troglitazone) was clin. tested with patients with impaired glucose tolerance by the WHO criteria; the results showed that treatment with troglitazone correlated to redn. of fasting insulin levels and return of glucose tolerance to the normal range for ~70% of the subjects.

IT **122320-73-4**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(thiazolidinedione derivs. in prevention of onset of noninsulin-dependent **diabetes**)

RN 122320-73-4 HCAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



```
=> d his

     (FILE 'HOME' ENTERED AT 20:08:06 ON 03 OCT 2002)

     FILE 'REGISTRY' ENTERED AT 20:08:18 ON 03 OCT 2002
L1              STRUCTURE UPLOADED
L2            2 S L1
L3           48 S L1 FULL

     FILE 'HCAPLUS' ENTERED AT 20:14:30 ON 03 OCT 2002
L4          490 S L3
L5          324 S L3/THU
L6           92 S L5 AND METHOD
L7           56 S L6 AND DIAB?
L8           44 S L7 AND MELLIT?
L9           17 S L8 AND PD < MAY 20 1999

=> s l3 and polymo?
          490 L3
       127960 POLYMO?
L10          7 L3 AND POLYMO?

=> s l10 and blackler, p?/au
            11 BLACKLER, P?/AU
L11          3 L10 AND BLACKLER, P?/AU

=> d l11, ibib abs fhitstr, 1-3

L11  ANSWER 1 OF 3  HCAPLUS  COPYRIGHT 2002 ACS
```

Full Text | Citing References

ACCESSION NUMBER: 2000:772629 HCAPLUS
DOCUMENT NUMBER: 133:340315
TITLE: Therapeutic action and properties of a **polymorphic** form of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, maleic acid salt
INVENTOR(S): **Blackler, Paul David James**; Browne, Christine Marie; Coakley, Timothy G.; Giles, Robert Gordon; Morrissey, Gillian
PATENT ASSIGNEE(S): SmithKline Beecham PLC, UK; SmithKline Beecham (Cork) Limited
SOURCE: PCT Int. Appl., 21 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000064896	A1	20001102	WO 2000-GB1520	20000419
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1173435	A1	20020123	EP 2000-920892	20000419
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 2000009932	A	20020409	BR 2000-9932	20000419
NO 2001005147	A	20011217	NO 2001-5147	20011022

PRIORITY APPLN. INFO.:

GB 1999-9473	A	19990423
GB 1999-12196	A	19990525
WO 2000-GB1520	W	20000419

AB A **polymorphic** form of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, maleic acid salt (the "**Polymorph**") characterized in that it provides: (i) an IR spectrum contg. peaks at 1763, 912, 856 and 709 cm^{-1}; and/or (ii) a Raman spectrum contg. peaks at 1762, 1284, 912 and 888 cm^{-1}; and/or (iii) a solid-state 13C NMR spectrum contg. peaks at 111.0, 113.6, 119.8, 129.1, 130.9, 131.8, 134.7, 138.7, 146.5, 152.7, 157.5, 169.5, 171.0, 178.7 ppm; and/or (iv) an x-ray powder diffraction (XRPD) pattern which gives calcd. lattice spacings at 5.87, 5.30, 4.69, 4.09, 3.88, 3.61, 3.53 and 3.46 Angstroms; a process for prepg. such a compd., a pharmaceutical compn. contg. such a compd. and the use of such a compd. in medicine.

IT **155141-29-0**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antidiabetic action and properties of **polymorphic** form of [[(N-methyl-N-(pyridyl)amino)ethoxy]benzyl]thiazolidinedione maleate)

RN 155141-29-0 HCAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 122320-73-4
CMF C18 H19 N3 O3 S

PAGE 1-A



PAGE 2-A



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2002 ACS

Full Text | Citing References

ACCESSION NUMBER: 2000:772627 HCAPLUS
DOCUMENT NUMBER: 133:340314
TITLE: Therapeutic action and properties of a **polymorphic** form of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, maleic acid salt
INVENTOR(S): **Blackler, Paul David James**; Giles, Robert Gordon; Moore, Stephen; Sasse, Michael John
PATENT ASSIGNEE(S): SmithKline Beecham PLC, UK
SOURCE: PCT Int. Appl., 19 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000064893	A2	20001102	WO 2000-GB1522	20000419
WO 2000064893	A3	20010125		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1175418	A2	20020130	EP 2000-922793	20000419
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 2000009935	A	20020416	BR 2000-9935	20000419
NO 2001005148	A	20011217	NO 2001-5148	20011022

PRIORITY APPLN. INFO.:

GB 1999-9471	A	19990423
GB 1999-12195	A	19990525
WO 2000-GB1522	W	20000419

AB A **polymorphic** form of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, maleic acid salt (the "**Polymorph**") characterized in that it provides: (i) an infra red spectrum contg. peaks at 1752, 1546, 1154, 621, and 602 cm^{-1}; and/or (ii) a Raman spectrum contg. peaks at 1751, 1243 and 602 cm^{-1}; and/or (iii) a solid-state NMR spectrum contg. peaks at 111.9, 114.8, 119.6, 129.2, 134.0, 138.0, 144.7, 153.2, 157.1, 170.7, 172.0 and 175.0 ppm; and/or (iv) an x-ray powder diffraction (XRPD) pattern which gives calcd. lattice spacings of 6.46, 5.39, 4.83, 4.68, 3.71, 3.63, 3.58, and 3.48 Angstroms; a process for prepg. such a compd., a pharmaceutical compn. contg. such a compd. and the use of such a compd. in medicine.

IT **168553-12-6**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antidiabetic action of **polymorphic** form of [[(N-methyl-N-(pyridyl)amino)ethoxy]benzyl]thiazolidinedione maleate)

RN 168553-12-6 HCAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-, (2Z)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 122320-73-4
CMF C18 H19 N3 O3 S

PAGE 1-A



PAGE 2-A



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



L11 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2002 ACS

Full Text | Citing References

ACCESSION NUMBER: 2000:772626 HCAPLUS
DOCUMENT NUMBER: 133:340313
TITLE: Therapeutic action and properties of a **polymorphic** form of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, maleic acid salt
INVENTOR(S): **Blackler, Paul David James**; Giles, Robert Gordon; Sasse, Michael John
PATENT ASSIGNEE(S): SmithKline Beecham P.L.C., UK
SOURCE: PCT Int. Appl., 18 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000064892	A2	20001102	WO 2000-GB1514	20000419
WO 2000064892	A3	20010125		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1173434	A2	20020123	EP 2000-920889	20000419
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 2000009934	A	20020604	BR 2000-9934	20000419
NO 2001005149	A	20011217	NO 2001-5149	20011022

PRIORITY APPLN. INFO.:			
GB 1999-9472	A	19990423	
GB 1999-12197	A	19990525	
WO 2000-GB1514	W	20000419	

AB A **polymorphic** form of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, maleic acid salt (the "**Polymorph**") characterized in that it: (i) provides an IR spectrum contg. peaks at 1360, 1326, 1241, 714 and 669 cm^{-1}; and/or (ii) provides a Raman spectrum contg. peaks at 1581, 768, 670, 271 and 226 cm^{-1}; and/or (iii) provides a solid-state NMR spectrum contg. peaks at chem. shifts substantially; and/or (iv) provides an x-ray powder diffraction (XRPD) pattern contg. peaks; a process for prepg. such a compd., a pharmaceutical compn. contg. such a compd. and the use of such a compd. in medicine.

IT **168553-12-6**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antidiabetic action of **polymorphic** form of [[(N-methyl-N-(pyridyl)amino)ethoxy]benzyl]thiazolidinedione maleate)

RN 168553-12-6 HCAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-, (2Z)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 122320-73-4
CMF C18 H19 N3 O3 S

PAGE 1-A



PAGE 2-A



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



=> **d his**

(FILE 'HOME' ENTERED AT 20:08:06 ON 03 OCT 2002)

FILE 'REGISTRY' ENTERED AT 20:08:18 ON 03 OCT 2002
L1 STRUCTURE UPLOADED
L2 2 S L1
L3 48 S L1 FULL

FILE 'HCAPLUS' ENTERED AT 20:14:30 ON 03 OCT 2002
L4 490 S L3
L5 324 S L3/THU
L6 92 S L5 AND METHOD
L7 56 S L6 AND DIAB?
L8 44 S L7 AND MELLIT?
L9 17 S L8 AND PD < MAY 20 1999
L10 7 S L3 AND POLYMO?
L11 3 S L10 AND BLACKLER, P?/AU

```
=> s l10 not l11
L12          4 L10 NOT L11

=> d l12, ibib abs fhitstr, 1-4

L12  ANSWER 1 OF 4  HCAPLUS  COPYRIGHT 2002 ACS
```

Full Text | Citing References

ACCESSION NUMBER: 2002:504785 HCAPLUS
DOCUMENT NUMBER: 137:83621
TITLE: Preparation and use of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione methanesulfonate
INVENTOR(S): Craig, Andrew Simon; Ho, Tim Chien Ting; Millan, Michael; O'Keeffe, Deirdre
PATENT ASSIGNEE(S): Smithkline Beecham P.L.C., UK
SOURCE: PCT Int. Appl., 41 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002051839	A1	20020704	WO 2001-GB5751	20011221

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:			
GB 2000-31521	A	20001222	
GB 2000-31524	A	20001222	
GB 2000-31526	A	20001222	
GB 2000-31528	A	20001222	

GI



I

AB A compd. 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione (I) methanesulfonate salt (II) or solvate thereof; a process for prepg. I, a compn. comprising I and its therapeutic use is disclosed. Four **polymorphic** forms were prepd. and characterized. For instance, MsOH (0.54 mL) was added to a mixt. of I (3.0 g) in EtOAc (60 mL) and was heated with agitation to reflux to give a suspension. The resulting mixt. was cooled to 21°C, the solid formed collected by filtration, washed with EtOAc and dried under vacuum for 16 h (3.73 g yield). **Polymorphic** forms I-IV were characterized by at least one of the following means: aq. soly., m.p., 1H-NMR (soln.), 13C-NMR (solid state), IR/Raman spectra, XRPD and DSC. II is a stable solid with good water soly., desirable flow properties and is amenable to large scale processing (milling). II is useful for the prevention/treatment of diabetes mellitus.

IT **439902-56-4P**
RL: IMF (Industrial manufacture); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(**polymorphic** forms I-IV characterized; prepn. and characterization of 5-[4-[2-(N-Me-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione methanesulfonate)
RN 439902-56-4 HCAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 122320-73-4
CMF C18 H19 N3 O3 S

PAGE 1-A



PAGE 2-A



CM 2

CRN 75-75-2
CMF C H4 O3 S



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2002 ACS

Full Text | Citing References

ACCESSION NUMBER: 2002:256258 HCAPLUS
DOCUMENT NUMBER: 136:299688
TITLE: Novel **polymorphic** forms of 5-[4-[2-[N-methyl-N-(2-pyridyl)amino]ethoxy]benzyl] thiazolidine-2,4-dione maleate and process for their preparation
INVENTOR(S): Chebiyyam, Prabhakar; Mamillapalli, Ramabhadra Sarma; Krishnamurthi, Vyas; Seella, Vishnuvardhan Reddy; Gaddam, Om Reddy
PATENT ASSIGNEE(S): Reddy's Research Foundation, India; Cord, Janet I.
SOURCE: PCT Int. Appl., 40 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002026737	A1	20020404	WO 2001-US29896	20010925
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2001091232	A5	20020408	AU 2001-91232	20010925

PRIORITY APPLN. INFO.:

IN 2000-MA805	A	20000926
WO 2001-US29896	W	20010925

AB This invention relates to novel **polymorphic**/pseudopolymorphic forms of 5-[4-[2[N-methyl-N-(2-pyridyl)amino]ethoxy]benzyl] thiazolidine-2,4-dione maleate (I). The invention also relates to a pharmaceutical compn. comprising the novel **polymorphic** form or their mixt. and a pharmaceutically acceptable carrier. The **polymorphic** forms of the present invention are more active, as antidiabetic agent, than the hitherto known 5-[4-[2-[N-2-methyl-N-(2-pyridyl)amino]ethoxy]benzyl] thiazolidine-2,4-dione maleate. I was dissolved in ethanol and was allowed to cool to room temp. over a period of 18 h to yield 80% of >99% pure **polymorphic** form of I.

IT **155141-29-0P**
RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(novel **polymorphic** forms of triazolidinedione maleate and process for their prepn.)

RN 155141-29-0 HCAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 122320-73-4
CMF C18 H19 N3 O3 S

PAGE 1-A



PAGE 2-A



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2002 ACS

Full Text | Citing References

ACCESSION NUMBER: 2001:724803 HCAPLUS
DOCUMENT NUMBER: 136:79548
TITLE: Inhibition of RXR and PPARγ ameliorates diet-induced obesity and type 2 diabetes
AUTHOR(S): Yamauchi, Toshimasa; Waki, Hironori; Kamon, Junji; Murakami, Koji; Motojima, Kiyoto; Komeda, Kajuro; Miki, Hiroshi; Kubota, Naoto; Terauchi, Yasuo; Tsuchida, Atsuko; Tsuboyama-Kasaoka, Nobuyo; Yamauchi, Naoko; Ide, Tomohiro; Hori, Wataru; Kato, Shigeaki; Fukayama, Masashi; Akanuma, Yasuo; Ezaki, Osamu; Itai, Akiko; Nagai, Ryozo; Kimura, Satoshi; Tobe, Kazuyuki; Kagechika, Hiroyuki; Shudo, Koichi; Kadowaki, Takashi
CORPORATE SOURCE: Department of Internal Medicine, Graduate School of Medicine, University of Tokyo, Tokyo, 113-8655, Japan

SOURCE: Journal of Clinical Investigation (2001), 108(7), 1001-1013
CODEN: JCINAO; ISSN: 0021-9738
PUBLISHER: American Society for Clinical Investigation
DOCUMENT TYPE: Journal
LANGUAGE: English

AB PPARγ is a ligand-activated transcription factor and functions as a heterodimer with a retinoid X receptor (RXR). Supraphysiol. activation of PPARγ by thiazolidinediones can reduce insulin resistance and hyperglycemia in type 2 diabetes, but these drugs can also cause wt. gain. Quite unexpectedly, a moderate redn. of PPARγ activity obsd. in heterozygous PPARγ-deficient mice or the Pro12Ala **polymorphism** in human PPARγ, has been shown to prevent insulin resistance and obesity induced by a high-fat diet. In this study, we investigated whether functional antagonism toward PPARγ/RXR could be used to treat obesity and type 2 diabetes. We show herein that an RXR antagonist and a PPARγ antagonist decrease triglyceride (TG) content in white adipose tissue, skeletal muscle, and liver. These inhibitors potentiated leptin's effects and increased fatty acid combustion and energy dissipation, thereby ameliorating HF diet-induced obesity and insulin resistance. Paradoxically, treatment of heterozygous PPARγ-deficient mice with an RXR antagonist or a PPARγ antagonist depletes white adipose tissue and markedly decreases leptin levels and energy dissipation, which increases TG content in skeletal muscle and the liver, thereby leading to the re-emergence of insulin resistance. Our data suggested that appropriate functional antagonism of PPARγ/RXR may be a logical approach to protection against obesity and related diseases such as type 2 diabetes.

IT **122320-73-4**, Rosiglitazone
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhibition of RXR and PPARγ ameliorates diet-induced obesity and type 2 diabetes)

RN 122320-73-4 HCAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A





REFERENCE COUNT: 55 THERE ARE 55 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2002 ACS

Full Text | Citing References

ACCESSION NUMBER: 1999:437778 HCAPLUS
DOCUMENT NUMBER: 131:197757
TITLE: Loss-of-function mutations in PPARγ associated with human colon cancer
AUTHOR(S): Sarraf, Pasha; Mueller, Elisabetta; Smith, Wendy M.; Wright, Harold M.; Kum, Jennifer B.; Aaltonen, Lauri A.; De la Chapelle, Albert; Spiegelman, Bruce M.; Eng, Charis
CORPORATE SOURCE: Department of Cancer Biology Dana-Farber Cancer Institute Department of Cell Biology, Harvard Medical School, Boston, MA, 02115, USA
SOURCE: Molecular Cell (1999), 3(6), 799-804
CODEN: MOCEFL; ISSN: 1097-2765
PUBLISHER: Cell Press
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The gamma isoform of the peroxisome proliferator-activated receptor, PPARγ, regulates adipocyte differentiation and has recently been shown to be expressed in neoplasia of the colon and other tissues. The authors have found four somatic PPARγ mutations among 55 sporadic colon cancers: one nonsense, one frameshift, and two missense mutations. Each greatly impaired the function of the protein. C.472delA results in deletion of the entire ligand binding domain. Q286P and K319X retain a total or partial ligand binding domain but lose the ability to activate transcription through a failure to bind to ligands. R288H showed a normal response to synthetic ligands but greatly decreased transcription and binding when exposed to natural ligands. These data indicate that colon cancer in humans is assocd. with loss-of-function mutations in PPARγ.

IT **122320-73-4**, BRL 49653
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(loss-of-function mutated PPARγ assocd. with human colon cancer binding of and transactivation response to)

RN 122320-73-4 HCAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> **file caold**

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	133.14	277.05

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-14.87	-14.87

FILE 'CAOLD' ENTERED AT 20:22:12 ON 03 OCT 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966
FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

This file supports REGlstRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

=> **d his**

```
     (FILE 'HOME' ENTERED AT 20:08:06 ON 03 OCT 2002)

     FILE 'REGISTRY' ENTERED AT 20:08:18 ON 03 OCT 2002
L1              STRUCTURE UPLOADED
L2            2 S L1
L3           48 S L1 FULL

     FILE 'HCAPLUS' ENTERED AT 20:14:30 ON 03 OCT 2002
L4          490 S L3
L5          324 S L3/THU
L6           92 S L5 AND METHOD
L7           56 S L6 AND DIAB?
L8           44 S L7 AND MELLIT?
L9           17 S L8 AND PD < MAY 20 1999
L10           7 S L3 AND POLYMO?
L11           3 S L10 AND BLACKLER, P?/AU
L12           4 S L10 NOT L11

     FILE 'CAOLD' ENTERED AT 20:22:12 ON 03 OCT 2002

=> s 13
L13           0 L3

=>
```

C:\stnweb\10019355.str



chain nodes :
7 10 11 12 14 23 24 30 31
ring nodes :
1 2 3 4 5 6 15 16 17 18 19 20 25 26 27 28 29
chain bonds :
7-10 7-11 11-12 12-14 14-17 20-23 23-24 24-27 25-31 28-30
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 15-16 15-20 16-17 17-18 18-19 19-20 25-26 25-29
26-27 27-28 28-29
exact/norm bonds :
7-10 12-14 14-17 25-29 25-31 28-29 28-30
exact bonds :
7-11 11-12 20-23 23-24 24-27 25-26 26-27 27-28
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 15-16 15-20 16-17 17-18 18-19 19-20
isolated ring systems :
containing 1 : 15 : 25 :

G1:CH3,Et

G2:O,S

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 10:CLASS 11:CLASS
12:CLASS 14:CLASS 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom 23:CLASS
24:CLASS 25:Atom 26:Atom 27:Atom 28:Atom 29:Atom 30:CLASS 31:CLASS